Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...

Detailed price information for Entrada Therapeutics Inc (TRDA-Q) from The Globe and Mail including charting and trades.

Janssen-Cilag International NV, a Johnson & Johnson company, has submitted an application to the European Medicines Agency ...

An elegant screening strategy unveils a molecular actor that connects widespread changes in mRNA processing with a nutrient-sensing protein modification.

Funding will enable company to expand research capacity and scale up unique genome editing technology designed to treat ...

Pink slips have followed the green light at Entrada Therapeutics. | Pink slips have followed the green light at Entrada ...

Sarepta Therapeutics Q1 2025 revenue beat expectations, but EPS missed, and cash reserves dropped significantly. Click here ...

Also in March 2025, Wave announced that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to ...

Type C meeting held in May 2025 for DYNE-101 in DM1 and Dyne plans to provide a regulatory update following receipt of meeting minutes - - Registrational Expansion Cohort of ACHIEVE Trial of DYNE-101 ...

Sarepta Therapeutics, Inc.’s SRPT share price has dipped by 19.10%, which has investors questioning if this is right time to ...